Amylyx PharmaceuticalsAMLX +2.59%33 PB Ratio is 7.09 as of Jun. 25, 2026, which is 93% above its 10-year median of 3.67. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks worse than 89.26% on this metric.
The historical rank and industry rank for Amylyx Pharmaceuticals's PB Ratio or its related term are showing as below:
AMLX'
s PB Ratio Range Over the Past 10 Years
Min: 0.34 Med: 3.67 Max: 15.94
Current: 7.09
During the past 7 years, Amylyx Pharmaceuticals's highest PB Ratio was 15.94. The lowest was 0.34. And the median was 3.67.
AMLX's PB Ratio is ranked worse than 89.26% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs AMLX: 7.09
During the past 12 months, Amylyx Pharmaceuticals's average Book Value Per Share Growth Rate was 8.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -18.40% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Amylyx Pharmaceuticals was -18.40% per year. The lowest was -18.40% per year. And the median was -18.40% per year.
Back to Basics: PB Ratio
Amylyx Pharmaceuticals (NAS:AMLX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Amylyx Pharmaceuticals (AMLX) has a PB Ratio of 7.09 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amylyx Pharmaceuticals and its competitors. This is 93% above median its historical median of 3.67. Over the past decade, Amylyx Pharmaceuticals' PB Ratio has ranged from 0.34 to 15.94. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #823 out of 922 companies in the Drug Manufacturers industry, placing it in the top 89.3%.
Is Amylyx Pharmaceuticals' PB Ratio too high?
Amylyx Pharmaceuticals' current PB Ratio of 7.09 is 93% above median its 10-year median of 3.67. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 15.94. The Drug Manufacturers industry median PB Ratio is 1.86. Amylyx Pharmaceuticals' value of 7.09 is 282.2% above this industry median. Based on the distribution chart, Amylyx Pharmaceuticals ranks #823 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' PB Ratio compare to PRGO and ANIP?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #823 out of 922 companies for PB Ratio. This places Amylyx Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.86. Amylyx Pharmaceuticals' value of 7.09 is 282.2% above this benchmark. Historically, Amylyx Pharmaceuticals' own PB Ratio has ranged from 0.34 to 15.94 over the past decade. While the company's 10-year median is 3.67 vs. the industry median of 1.86, Amylyx Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amylyx Pharmaceuticals's current PB Ratio of 7.09 is 282.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current PB Ratio is 7.09, which is 93% above median its own 10-year median of 3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current PB Ratio of 7.09. The current PB Ratio is 7.09, which is 93% above median its 10-year median of 3.67 and 282.2% above the Drug Manufacturers industry median of 1.86. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current PB Ratio is 7.09 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
